Not recruiting
Triple negative breast cancer
Not recruitingStudy of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy
Registered drugNo placebo
Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy
Registered drugNo placebo
- Disease:Triple negative breast cancer
- Substances:CapecitabineDurvalumab+4
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:AstraZeneca AB
